Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAtea Pharmaceuticals Inc

Atea Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
4.22 USD 0.02 ( 0.48%)
Last update at 2026-11-11T20:54:00Z
VOLUME
258135
Market Cap
454.93M

Momentum Score

…

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.04
Low
4.34
High
52 Week Price Range
2.46
Low
6.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Atea Pharmaceuticals is a clinical-stage company developing oral antiviral therapeutics for respiratory and systemic viral infections. Long-term growth may be driven by clinical trial progress, regulatory approvals, commercialization or licensing of lead candidates, and continued global demand for outpatient antiviral treatments, which could make the company attractive to investors seeking exposure to antiviral drug development.
The primary investment risks are a high probability of clinical or regulatory failure, dependence on a small number of development-stage assets with limited revenue, ongoing cash burn that may require additional financing, and strong competition from established and emerging antivirals.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.20
Dividend Yield
-
Revenue TTM
192.18M
Revenue Per Share
2.31
Gross Profit TTM
-146.53M
Debt / Equity
0.00
ROE
-44.34%
Net Debt
-94.87M
ROCE
-65.82%
Diluted EPS TTM
-1.94

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -164.51M -167.46M -134.94M -119.50M 138.59M
Net income -158.35M -168.38M -135.96M -115.91M 121.19M
Selling general administrative 32.86M 48.85M 49.92M 48.71M 45.78M
Selling and marketing expenses - - 49.45M - -
Gross profit -0.42M -83.37M -70.09M - 351.37M
Reconciled depreciation 0.42M 0.42M 0.42M 0.26M 0.03M
Ebit -181.30M -132.22M -120.01M -130.91M 138.35M
Ebitda -180.89M -131.80M -119.59M -130.65M 138.38M
Depreciation and amortization 0.42M 0.42M 0.42M 0.26M 0.03M
Non operating income net other - - - - 0.21M
Operating income -180.89M -192.95M -164.16M -130.65M 138.38M
Other operating expenses 180.89M 192.95M 164.16M 130.65M 212.99M
Interest expense - - - 11.15M 0.24M
Tax provision -6.16M 0.93M 1.02M -3.59M 17.40M
Interest income 16.38M 25.49M 29.22M 11.15M 0.21M
Net interest income 16.38M 25.49M 29.22M 11.15M 0.21M
Income tax expense -6.16M 0.93M 1.02M -3.59M 17.40M
Total revenue 0.00M 0.00M 0.00M 0.00M 351.37M
Total operating expenses 180.89M 109.58M 94.07M 130.65M 212.99M
Cost of revenue 0.42M 83.37M 70.09M - -
Total other income expense net 16.38M 25.49M 29.22M 11.15M 0.21M
Net income from continuing ops -158.35M -168.38M -135.96M -115.91M 121.19M
Net income applicable to common shares - - - -115.91M 121.19M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 315.22M 464.67M 594.97M 666.71M 772.89M
Other current assets 9.16M 7.63M 12.35M 14.21M 8.03M
Total liab 39.78M 25.80M 39.78M 26.14M 62.81M
Total stockholder equity 275.43M 438.87M 555.19M 640.57M 710.08M
Other current liab 26.00M 13.35M 27.36M 15.21M 52.35M
Common stock 0.08M 0.08M 0.08M 0.08M 0.08M
Capital stock 0.08M 0.08M 0.08M 0.08M 0.08M
Retained earnings -522.57M -364.22M -195.84M -59.88M 56.03M
Other liab - - - 5.25M 5.93M
Other assets - - 0.00M 1.69M 0.47M
Cash 95.71M 64.70M 143.82M 646.71M 764.38M
Total current liabilities 39.78M 18.60M 32.38M 18.48M 56.88M
Current deferred revenue - - -0.00M - -
Net debt -94.87M -63.05M -141.42M -643.59M -764.38M
Short term debt 0.84M 0.80M 0.76M 0.72M -
Short long term debt total 0.84M 1.64M 2.40M 3.12M -
Other stockholder equity 797.75M 802.77M 750.74M 701.05M 653.96M
Property plant equipment - - - 4.09M 0.02M
Total current assets 310.99M 462.36M 590.46M 660.92M 772.40M
Net tangible assets - - - 640.57M 710.08M
Short term investments 206.12M 390.02M 434.28M 458.25M -
Accounts payable 12.95M 4.46M 4.25M 2.55M 4.53M
Accumulated other comprehensive income 0.17M 0.23M 0.21M -0.68M -
Common stock total equity - - - - 0.08M
Retained earnings total equity - - - - 56.03M
Non currrent assets other 3.14M 0.20M 1.40M 1.69M 0.47M
Non current assets total 4.23M 2.31M 4.51M 5.79M 0.49M
Capital lease obligations 0.84M 1.64M 2.40M 3.12M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 188.79M 56.10M 40.30M -455.41M -0.00M
Change to liabilities - - - -1.98M -291.08M
Total cashflows from investing activities 188.79M 56.10M 40.30M -455.41M -0.00M
Total cash from financing activities -25.75M 0.27M 0.26M 0.37M 1.47M
Change to operating activities - - - -44.60M 43.23M
Net income -158.35M -168.38M -135.96M -115.91M 121.19M
Change in cash 31.02M -79.13M -44.84M -576.02M -85.54M
Begin period cash flow 64.70M 143.82M 188.66M 764.68M 850.22M
End period cash flow 95.71M 64.70M 143.82M 188.66M 764.68M
Total cash from operating activities -132.03M -135.50M -85.39M -120.98M -87.00M
Issuance of capital stock 0.06M 0.00M - 0.23M 1.47M
Depreciation 0.42M 0.42M 0.42M 0.26M 0.03M
Sale purchase of stock -25.52M 0.00M - - 1.47M
Other cashflows from financing activities -0.48M 0.27M 0.26M 0.14M -0.00M
Change to netincome - - - 41.25M 39.62M
Capital expenditures 0.00M 0.00M 0.00M 1.94M 0.00M
Cash flows other operating - - - - -302.01M
Cash and cash equivalents changes - - - - -85.54M
Change in working capital 16.48M -7.48M 16.16M -46.59M -247.84M
Stock based compensation 20.72M 51.77M 49.43M 46.72M 39.62M
Other non cash items -4.94M -11.82M 33.11M -5.46M -415.68M
Free cash flow -132.03M -135.50M -85.39M -122.92M -87.01M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AVIR
Atea Pharmaceuticals Inc		 0.02
0.48%		 4.22 - - 1.55 1.66 58.97 -260.47
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Atea Pharmaceuticals Inc

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

225 Franklin Street, Boston, MA, United States, 02110

857 284 8891

https://ateapharma.com

55

Name Title Year Born
Dr. Jean-Pierre Sommadossi Ph.D. Founder, Chairman, CEO & Pres 1956
Ms. Andrea J. Corcoran J.D. CFO, Exec. VP of Legal & Sec. 1962
Mr. John F. Vavricka Chief Commercial Officer 1964
Dr. Janet M. J. Hammond M.D., Ph.D. Chief Devel. Officer 1960
Dr. Maria Arantxa Horga M.D. Chief Medical Officer 1968
Mr. Wayne Foster CPA, CPA Exec. VP of Fin. & Chief Accounting Officer 1969
Ms. Jonae R. Barnes Sr. VP of Investor Relations & Corp. Communications NA
Mr. Ariyapadi N. Krishnaraj VP of Marketing NA
Mr. Adel Moussa Ph.D. Exec. VP of Chemistry NA
Mr. Xiao-Jian Zhou Ph.D. Exec. VP of Early Stage Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…